Rocket One subsidiary Hoth ends HT-001 Phase 2a trial early after positive interim results
HOTH•Hoth Therapeutics will end its Phase 2a HT-001 trial early after positive interim efficacy results. The company plans to seek FDA feedback on a potential Phase 3 program, whose start depends on regulatory feedback and required development work.
1. Trial ends early
Hoth Therapeutics, a Rocket One subsidiary, will end its Phase 2a trial of investigational HT-001 early following positive interim efficacy results. The treatment targets skin toxicities associated with EGFR inhibitor cancer therapies; Hoth plans to seek FDA feedback on a potential Phase 3 program.
